These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31043521)

  • 1. A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder.
    Bolognani F; Del Valle Rubido M; Squassante L; Wandel C; Derks M; Murtagh L; Sevigny J; Khwaja O; Umbricht D; Fontoura P
    Sci Transl Med; 2019 May; 11(491):. PubMed ID: 31043521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial.
    Jacob S; Veenstra-VanderWeele J; Murphy D; McCracken J; Smith J; Sanders K; Meyenberg C; Wiese T; Deol-Bhullar G; Wandel C; Ashford E; Anagnostou E
    Lancet Psychiatry; 2022 Mar; 9(3):199-210. PubMed ID: 35151410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder.
    Schnider P; Bissantz C; Bruns A; Dolente C; Goetschi E; Jakob-Roetne R; Künnecke B; Mueggler T; Muster W; Parrott N; Pinard E; Ratni H; Risterucci C; Rogers-Evans M; von Kienlin M; Grundschober C
    J Med Chem; 2020 Feb; 63(4):1511-1525. PubMed ID: 31951127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial.
    Hollander E; Jacob S; Jou R; McNamara N; Sikich L; Tobe R; Smith J; Sanders K; Squassante L; Murtagh L; Gleissl T; Wandel C; Veenstra-VanderWeele J
    JAMA Psychiatry; 2022 Aug; 79(8):760-769. PubMed ID: 35793101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program.
    Jacob S; Anagnostou E; Hollander E; Jou R; McNamara N; Sikich L; Tobe R; Murphy D; McCracken J; Ashford E; Chatham C; Clinch S; Smith J; Sanders K; Murtagh L; Noeldeke J; Veenstra-VanderWeele J
    Mol Autism; 2022 Jun; 13(1):25. PubMed ID: 35690870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers.
    Derks M; Lennon-Chrimes S; Guenther A; Squassante L; Wandel C; Szczesny P; Paehler A; Kletzl H
    Expert Opin Investig Drugs; 2021 Aug; 30(8):893-901. PubMed ID: 34176392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder.
    Umbricht D; Del Valle Rubido M; Hollander E; McCracken JT; Shic F; Scahill L; Noeldeke J; Boak L; Khwaja O; Squassante L; Grundschober C; Kletzl H; Fontoura P
    Neuropsychopharmacology; 2017 Aug; 42(9):1914-1923. PubMed ID: 27711048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive behavior in autism: Minimal clinically important differences on the Vineland-II.
    Chatham CH; Taylor KI; Charman T; Liogier D'ardhuy X; Eule E; Fedele A; Hardan AY; Loth E; Murtagh L; Del Valle Rubido M; San Jose Caceres A; Sevigny J; Sikich L; Snyder L; Tillmann JE; Ventola PE; Walton-Bowen KL; Wang PP; Willgoss T; Bolognani F
    Autism Res; 2018 Feb; 11(2):270-283. PubMed ID: 28941213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder.
    Schmitt LM; Smith EG; Pedapati EV; Horn PS; Will M; Lamy M; Barber L; Trebley J; Meyer K; Heiman M; West KHJ; Hughes P; Ahuja S; Erickson CA
    Sci Rep; 2023 Mar; 13(1):5192. PubMed ID: 36997569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism.
    Parker KJ; Oztan O; Libove RA; Mohsin N; Karhson DS; Sumiyoshi RD; Summers JE; Hinman KE; Motonaga KS; Phillips JM; Carson DS; Fung LK; Garner JP; Hardan AY
    Sci Transl Med; 2019 May; 11(491):. PubMed ID: 31043522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder.
    Tobe R; Zhu Y; Gleissl T; Rossomanno S; Veenstra-VanderWeele J; Smith J; Hollander E
    Neuropsychopharmacology; 2023 Jul; 48(8):1201-1216. PubMed ID: 37045991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylphenidate for children and adolescents with autism spectrum disorder.
    Sturman N; Deckx L; van Driel ML
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011144. PubMed ID: 29159857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New V1a receptor antagonist. Part 1. Synthesis and SAR development of urea derivatives.
    Szántó G; Makó A; Baska F; Bozó É; Domány-Kovács K; Kurkó D; Cselenyák A; Mohácsi R; Kordás KS; Bata I
    Bioorg Med Chem Lett; 2020 Sep; 30(18):127416. PubMed ID: 32736211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, effectiveness, and economic evaluation of an herbal medicine, Ukgansangajinpibanha granule, in children with autism spectrum disorder: a study protocol for a prospective, multicenter, randomized, double-blinded, placebo-controlled, parallel-group clinical trial.
    Lee SH; Shin S; Kim TH; Kim SM; Do TY; Park S; Lee B; Shin HJ; Lee J; Lee JY; Chang GT
    Trials; 2019 Jul; 20(1):434. PubMed ID: 31307524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New V1a receptor antagonist. Part 2. Identification and optimization of triazolobenzazepines.
    Bozó É; Baska F; Lövei K; Szántó G; Domány-Kovács K; Kurkó D; Szondiné Kordás K; Szokoli T; Bata I
    Bioorg Med Chem Lett; 2020 Sep; 30(18):127417. PubMed ID: 32731087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up.
    Bernaerts S; Boets B; Bosmans G; Steyaert J; Alaerts K
    Mol Autism; 2020; 11(1):6. PubMed ID: 31969977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial.
    Guastella AJ; Gray KM; Rinehart NJ; Alvares GA; Tonge BJ; Hickie IB; Keating CM; Cacciotti-Saija C; Einfeld SL
    J Child Psychol Psychiatry; 2015 Apr; 56(4):444-52. PubMed ID: 25087908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everyday executive function predicts adaptive and internalizing behavior among children with and without autism spectrum disorder.
    Gardiner E; Iarocci G
    Autism Res; 2018 Feb; 11(2):284-295. PubMed ID: 28960841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled trial of vitamin D supplementation in children with autism spectrum disorder.
    Saad K; Abdel-Rahman AA; Elserogy YM; Al-Atram AA; El-Houfey AA; Othman HA; Bjørklund G; Jia F; Urbina MA; Abo-Elela MGM; Ahmad FA; Abd El-Baseer KA; Ahmed AE; Abdel-Salam AM
    J Child Psychol Psychiatry; 2018 Jan; 59(1):20-29. PubMed ID: 27868194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial.
    Veenstra-VanderWeele J; Cook EH; King BH; Zarevics P; Cherubini M; Walton-Bowen K; Bear MF; Wang PP; Carpenter RL
    Neuropsychopharmacology; 2017 Jun; 42(7):1390-1398. PubMed ID: 27748740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.